Acrivon Therapeutics Stock Rises 14% On FDA Recognition For ACR-368 OncoSignature Assay
Acrivon Therapeutics, Inc. (ACRV) is up by 14 percent on Wednesday. The stock surged after the company announced that the U.S. Food ...
Acrivon Therapeutics:FDA Grants Breakthrough Device Designation For ACR-368 OncoSignature Assay
The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...